New approach methodologies (NAMs): The enabling role of bioprinting
Animal-based preclinical testing is increasingly misaligned with the biological and regulatory demands of modern drug development. Persistent failure of drug candidates underscores the limitations of using animal models for human drug development. In oncology and neurodegeneration, where disease mechanisms and therapeu...